-
Biomanufacturing Company Gains $9.5M in Early Funds
A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round.
-
Industry-Academic Center to Boost Rare Disease Therapies
An alliance of academic labs and venture investors is starting a new research enterprise to speed development of treatments for rare diseases in the U.S. and U.K.
-
FDA Clears Genetic Cancer Risk Detection Test
The Food and Drug Administration authorized marketing of a genetic test for detecting hundreds of gene variants associated with a higher risk of developing certain cancers.
-
Infographic – Biotech Index Continues Downward Trend
The Nasdaq Biotechnology Index, an indicator of investor sentiment in an industry based on science, continued heading down during the third quarter of 2023.
-
Biotech Thymus Tissue Process Gains ARPA-H Funding
A company with a process to generate new thymus tissue for immune system functions is receiving a $37 million award from the government’s health breakthrough agency.
-
Cardiac Tech Start-Up Partners with Mayo Clinic
A new company developing digital cardiac diagnostics is collaborating with the Mayo Clinic on early detection of coronary artery disease, a key trigger of heart attacks.
-
Trial Shows Broad Coronavirus Immune Response
Initial results from a clinical trial show an experimental vaccine produces immune responses in healthy adults against Covid-19 variants and a range of other coronaviruses.
-
Small Biz Award Funds Wearable Drug Delivery Patch
A developer of medical devices designed as skin patches received a contract to develop a device to deliver any drug approved by FDA for delivery through the skin.
-
Infographic – Deaths From Nipah Virus
Nipah virus is a rare but deadly infectious disease affecting south and southeast Asia, and since August the Kerala state in India recorded six Nipah cases leading to two deaths.
-
FDA Clears Biotech Seasonal Flu Treatment Trial
A start-up biotechnology company says it received the okay for its investigational new drug application of an anti-viral drug to treat a whole class of seasonal flu strains.